FDA Warns Novo Nordisk Over Ozempic Safety Reporting Failures and Deaths

# SEO-Friendly Podcast Episode Description ## Navigating Ozempic: FDA Warning, Vision Risks & Life After GLP-1 Drugs Discover the latest critical updates on Ozempic and GLP-1 medications in this must-listen episode of Navigating Ozempic. We break down three major developments that could impact millions of diabetes and weight loss patients. **What You'll Learn:** 🔴 **FDA Warning to Novo Nordisk** - Breaking down the serious compliance violations involving unreported adverse events, including three patient deaths and delayed safety reports over 800 days late 👁️ **New Vision Risk Research** - Learn about the British Journal of Ophthalmology study linking Wegovy to nearly 5x higher risk of NAION (eye stroke) and what this means for all GLP-1 users ✅ **Hope for Long-Term Success** - Groundbreaking Cleveland Clinic study reveals patients who stop Ozempic may avoid weight regain with proper support, challenging common misconceptions **Key Topics Covered:** - Ozempic safety concerns and FDA oversight - Semaglutide and tirzepatide side effects - Type 2 diabetes management strategies - Weight loss medication alternatives - GLP-1 drug lawsuits and legal developments - Post-treatment success strategies Perfect for patients currently using Ozempic, Wegovy, or other GLP-1 medications, healthcare providers, and anyone considering these treatments for diabetes or weight management. **Episode Length:** [Duration] **Host:** Navigating Ozempic Podcast **Production:** Quiet Please Subscribe for weekly evidence-based updates on GLP-1 medications and diabetes care. --- *Keywords: Ozempic, GLP-1 drugs, semaglutide, FDA warning, Novo Nordisk, weight loss medication, type 2 diabetes, Wegovy, NAION vision risk, medication safety* Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai This content was created in partnership and with the help of Artificial Intelligence AI.